Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3909877 | The Breast | 2007 | 9 Pages |
SummaryEstrogen receptor (ER) status can predict the efficacy of endocrine therapy. However, the predictive significance of the progesterone receptor (PgR) is controversial in an adjuvant setting. Records of 758 ER+ breast cancer patients who received adjuvant tamoxifen (TAM) for 3–5 years were reviewed to evaluate the predictive value of PgR for TAM treatment in ER+/PgR+ and ER+/PgR− groups. By a median of 40 months’ follow-up, there was no significant difference between the two groups with regard to disease-free-survival (DFS). On the basis of STEPP analysis showing the tendency of age effect on DFS in both the ER+/PgR− and ER+/PgR+ groups, we classified the ER+ patients into three strata by age (<45, 45–60, and⩾60 years). There was no significant difference in DFS and overall survival (OS) between the two groups in the <45 stratum and the 45–60 stratum. In contrast, the ER+/PgR− group had a worse prognosis in the ⩾60 stratum with regard to both DFS (P=0.0484) and OS (P=0.0009). The results suggest that PgR status might be a predictive factor of benefit to be gained from adjuvant TAM for older ER+ patients with regard to DFS and OS. This should take into account older ER+/PgR− patients who tend to be resistant to TAM.